Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
JAK inhibitors; allogeneic stem cell transplant; fibrosis; mylelofibrosis; relapse
Abstract :
[en] Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
Disciplines :
Hematology
Author, co-author :
McLornan, Donal P.
Szydlo, Richard
Robin, Marie
van Biezen, Anja
Koster, Linda
Blok, Henrik J. P.
Van Lint, Maria T.
Finke, Jurgen
Vitek, Antonin
Carlson, Kristina
Griskevicius, Laimonas
Holler, Ernst
Itala-Remes, Maija
Schaap, Michel
Socie, Gerard
Bay, Jacques-Olivier
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
Janson, D., Ayuk, F.A., Wolschke, C., Christopeit, M., Badbaran, A., von Pein, U.M., van Randenborgh, A. & Kroeger, N. (2016) Ruxolitinib for myelofibrosis patients relapsing after allogeneic hematopoietic transplantation. Blood, 128, 1948.
Klyuchnikov, E., Holler, E., Bornhäuser, M., Kobbe, G., Nagler, A., Shimoni, A., Könecke, C., Wolschke, C., Bacher, U., Zander, A.R. & Kröger, N. (2012) Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. British Journal of Haematology, 159, 172–181.
Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009a) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 5264–5270.
Kröger, N., Alchalby, H., Klyuchnikov, E., Badbaran, A., Hildebrandt, Y., Ayuk, F., Bacher, U., Bock, O., Kvasnicka, M., Fehse, B. & Zander, A. (2009b) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood, 113, 1866–1868.
Kröger, N.M., Deeg, J.H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., Rambaldi, A., Mesa, R., Tefferi, A., Griesshammer, M., Gupta, V., Harrison, C., Alchalby, H., Vannucchi, A.M., Cervantes, F., Robin, M., Ditschkowski, M., Fauble, V., McLornan, D., Ballen, K., Popat, U.R., Passamonti, F., Rondelli, D. & Barosi, G. (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 29, 2126–2133.
McLornan, D.P., Mead, A.J., Jackson, G. & Harrison, C.N. (2012) Allogeneic stem cell transplantation for myelofibrosis in 2012. British Journal of Haematology, 157, 413–425.
Shanavas, M., Popat, U., Michaelis, L.C., Fauble, V., McLornan, D., Klisovic, R., Mascarenhas, J., Tamari, R., Arcasoy, M.O., Davies, J., Gergis, U., Ukaegbu, O.C., Kamble, R.T., Storring, J.M., Majhail, N.S., Romee, R., Verstovsek, S., Pagliuca, A., Vasu, S., Ernst, B., Atenafu, E.G., Hanif, A., Champlin, R., Hari, P. & Gupta, V. (2016) Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus Kinase 1/2 inhibitors. Biology of Blood Marrow Transplantation, 22, 432–440.
